27.00
price down icon1.71%   -0.50
after-market Dopo l'orario di chiusura: 27.00
loading

Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie

pulisher
Nov 20, 2024

First Week of January 2025 Options Trading For Spyre Therapeutics - Nasdaq

Nov 20, 2024
pulisher
Nov 20, 2024

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out - AccessWire

Nov 20, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics Prices of $200 Million Public Offering of Common Stock - citybiz

Nov 19, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap DownShould You Sell? - MarketBeat

Nov 19, 2024
pulisher
Nov 19, 2024

Spyre Therapeutics announces pricing of $200 million public offering of common stock - MSN

Nov 19, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Launches $200M Public Offering for IBD Treatment Development | SYRE Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - PR Newswire

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics revises net loss per share calculations - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics launches $200 million public offering - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Spyre Therapeutics Launches $200M Public Stock Offering for IBD Drug Development | SYRE Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 15, 2024

Wedbush Expects Weaker Earnings for Spyre Therapeutics - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Perceptive Advisors LLC Reduces Stake in Spyre Therapeutics Inc - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

SYRE Crosses Below Key Moving Average Level - Nasdaq

Nov 14, 2024
pulisher
Nov 14, 2024

Avoro Capital Advisors LLC Adjusts Stake in Spyre Therapeutics I - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Deep Track Capital, LP Adjusts Stake in Spyre Therapeutics Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Robert W. Baird Increases Spyre Therapeutics (NASDAQ:SYRE) Price Target to $65.00 - MarketBeat

Nov 13, 2024
pulisher
Nov 13, 2024

Spyre reports promising Phase 1 results for IBD therapy By Investing.com - Investing.com Australia

Nov 13, 2024
pulisher
Nov 13, 2024

FMR LLC Acquires Additional Shares in Spyre Therapeutics Inc - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Equities Analysts Offer Predictions for SYRE Q1 Earnings - Defense World

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre reports promising Phase 1 results for IBD therapy - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre's IBD Drug Shows Breakthrough 90-Day Half-Life in Phase 1 Trial, 4x Better Than Standard | SYRE Stock News - StockTitan

Nov 12, 2024
pulisher
Nov 12, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $46.43 Average PT from Brokerages - Defense World

Nov 12, 2024
pulisher
Nov 11, 2024

Spyre Therapeutics to Reveal Key IBD Drug Trial Data: SPY001 Results Coming Nov 12 | SYRE Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 11, 2024

Q1 Earnings Estimate for SYRE Issued By Wedbush - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE) - MarketBeat

Nov 09, 2024
pulisher
Nov 09, 2024

Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock - Investing.com India

Nov 09, 2024
pulisher
Nov 09, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Rating of "Buy" by Analysts - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics director Jeffrey Albers sells $246,312 in stock By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics: Q3 Earnings Snapshot - Thehour.com

Nov 08, 2024
pulisher
Nov 08, 2024

Spyre Therapeutics Advances IBD Treatment Pipeline - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Nov 07, 2024
pulisher
Nov 03, 2024

292,569 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Emerald Advisers LLC - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire

Nov 01, 2024
pulisher
Oct 30, 2024

Spyre Therapeutics to Participate in Upcoming November Investor Conferences - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Spyre Therapeutics (NASDAQ:SYRE) Price Target Increased to $65.00 by Analysts at Guggenheim - Defense World

Oct 29, 2024
pulisher
Oct 29, 2024

Spyre Therapeutics director sells shares worth $10,929 - Investing.com India

Oct 29, 2024
pulisher
Oct 28, 2024

Spyre Therapeutics director sells shares worth $10,929 By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 28, 2024

Jeffrey W. Albers Sells 300 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Spyre Therapeutics' Catalyst Cascade On Track For Late 2024 - RTTNews

Oct 26, 2024
pulisher
Oct 25, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap UpHere's Why - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Assenagon Asset Management S.A. Acquires New Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Oct 25, 2024
pulisher
Oct 18, 2024

SPY-003, an extended half-life MAb with twice-a-year projected human maintenance dosing - BioWorld Online

Oct 18, 2024
pulisher
Oct 18, 2024

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $43.43 - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 4.5%Time to Buy? - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance

Oct 17, 2024
pulisher
Oct 16, 2024

Results from Spyre Therapeutics Inc. (SYRE) show potential - US Post News

Oct 16, 2024
pulisher
Oct 15, 2024

Wedbush’s latest rating for SYRE stock - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

SYRE’s 2023 Market Dance: Up 42.47% – Time to Invest? - The InvestChronicle

Oct 15, 2024
pulisher
Oct 15, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $43.43 Consensus PT from Analysts - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Spyre Therapeutics Advances SPY003 for IBD Treatment - TipRanks

Oct 15, 2024
pulisher
Oct 14, 2024

Spyre shares rise on positive SPY003 data, analyst maintains Buy By Investing.com - Investing.com UK

Oct 14, 2024
pulisher
Oct 14, 2024

Spyre Therapeutics advances IBD antibody treatments - Investing.com

Oct 14, 2024
pulisher
Oct 14, 2024

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations - PR Newswire

Oct 14, 2024
pulisher
Oct 14, 2024

The Manufacturers Life Insurance Company Takes $888,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Oct 14, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.56%
$367.36
price up icon 0.77%
$194.56
price up icon 0.07%
$108.23
price up icon 5.98%
Capitalizzazione:     |  Volume (24 ore):